Algert Global LLC Buys 100,104 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Algert Global LLC raised its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 106.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 193,804 shares of the biotechnology company's stock after acquiring an additional 100,104 shares during the quarter. Algert Global LLC owned 0.14% of Aurinia Pharmaceuticals worth $1,107,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $30,000. Cantor Fitzgerald L. P. lifted its stake in Aurinia Pharmaceuticals by 44.7% during the fourth quarter. Cantor Fitzgerald L. P. now owns 145,310 shares of the biotechnology company's stock valued at $1,306,000 after buying an additional 44,855 shares in the last quarter. Sierra Summit Advisors LLC acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $202,000. Goldman Sachs Group Inc. increased its position in shares of Aurinia Pharmaceuticals by 39.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,048,456 shares of the biotechnology company's stock worth $18,416,000 after acquiring an additional 576,120 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 7.1% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 75,787 shares of the biotechnology company's stock valued at $380,000 after acquiring an additional 5,043 shares during the period. 36.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright restated a "buy" rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, Aurinia Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $10.00.

Insider Activity

In other news, insider Scott Michael Habig sold 18,249 shares of the firm's stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the completion of the sale, the insider now owns 456,338 shares of the company's stock, valued at approximately $2,423,154.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 4.30% of the stock is owned by corporate insiders.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ AUPH traded up $0.10 during trading hours on Friday, hitting $7.12. 820,387 shares of the company's stock were exchanged, compared to its average volume of 1,682,421. The company's 50-day moving average price is $6.52 and its 200-day moving average price is $5.74. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.05. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -16.56 and a beta of 1.44. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.33 and a quick ratio of 4.82.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 EPS for the quarter, hitting analysts' consensus estimates of $0.01. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The company had revenue of $57.10 million during the quarter, compared to analyst estimates of $54.25 million. During the same period in the previous year, the company earned ($0.08) earnings per share. The company's quarterly revenue was up 37.6% compared to the same quarter last year. On average, sell-side analysts expect that Aurinia Pharmaceuticals Inc. will post 0.13 earnings per share for the current fiscal year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.